September 30, 2017
5-year project aims to reduce the disease burden of age-related macular degeneration in Europe and worldwide.
A new European-wide project involving researchers from City, University of London aims to develop new tests and therapies for age-related macular degeneration (AMD).
The MACUSTAR project, which involves several European universities, medical-technology and pharmaceutical companies, will develop these clinical tests and therapeutic options over the course of the 5-year project to help reduce the disease burden of AMD in Europe and worldwide. The project is funded with 16 million euros and is being led by the University of Bonn, Germany.
MACUSTAR is the first exclusively eye disease-focused project approved by the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
Central to MACUSTAR is the development of a series of tests for worsening of AMD using state of the art imaging techniques, vision testing and patient reported outcome measures. The main idea is to test these novel approaches to see if subtle changes in AMD can be accurately detected over time. If this is achieved then it will lead to more efficient clinical trials for new treatments for AMD and accelerate drug development. The main costs for the MACUSTAR project are for a huge observational clinical study to be conducted in more than 700 AMD patients from 20 clinical sites across Europe.
For more info:
September 23, 2017
Researchers at Massachusetts Eye and Ear have discovered a group of metabolites that could be used to improve the diagnosis and treatment of AMD.
The Massachusetts Eye and Ear team studied metabolites, or small molecules in the blood of patients with early, intermediate and late-stage AMD, as well as from individuals without AMD.
They found 87 metabolites that were “significantly different” in people with AMD and those without. These molecules also differed between patients with different stages of AMD. This method, dubbed “metabolomics,” could enable the early diagnosis of AMD, allow doctors to personalize treatment for each patient and highlight potential new targets for treatments. The work is published in the journal Ophthalmology, sited below.
For more info:
September 17, 2017
If you are an individual experiencing limited eyesight for all kinds of reasons, which could be cataracts, glaucoma, macular degeneration, detached retina, etc., this information might be useful for you. Your ophthalmologist will not tell you this information and you’ll have to find it through a low-vision occupational therapist and other resources. To assist you, we have been writing this blog for over 8 years, sharing the low vision information we find with thousands of readers throughout the world
If you’re struggling using your computer, you might want to use Zoom Text. You can download a trial version of Zoom Text and see if it is any help to you. Zoom Text has a magnification and reading feature that can be adjusted to your eyesight limitations. I strongly recommend downloading a trial version of Zoom Text to see if this might be helpful.
We also recommend that you connect with a low-vision occupational therapist. You might contact Therapeutic Solutions in Raleigh, NC. There are other low-vision occupational therapists throughout the country . These low-vision occupational therapists will meet you where you are at, at the time. They will help you maintain your independence and show you how you can use an iPad, as an example, for your transportation needs.
Continue to read this blog as it will give you a lot of information along these lines found by John Logan. It is important that you become your own advocate.